Opportunities Preloader

Please Wait.....

Report

Chemotherapy Induced Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Industry Report I 2022-05-31 I 51 Pages I Global Markets Direct

Chemotherapy Induced Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Drugs In Development, 2022, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 1, 5 and 2 respectively.

Chemotherapy Induced Anemia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Anemia (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Anemia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Anemia (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Anemia - Overview
Chemotherapy Induced Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chemotherapy Induced Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
Avesthagen Ltd
FibroGen Inc
General Biologics Inc
Imagine Pharma LLC
Jecho Biopharmaceuticals Co Ltd
Panacea Biotec Ltd
PharmaEssentia Corp
PhytoHealth Corp
Resilience Biotechnologies Inc
SBI Pharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Oncology, Inc
UBI Pharma Inc
Vifor Pharma Ltd
Zydus Lifesciences Ltd
Chemotherapy Induced Anemia - Drug Profiles
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
Product Description
Mechanism Of Action
History of Events
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
desidustat - Drug Profile
Product Description
Mechanism Of Action
History of Events
epoetin alfa - Drug Profile
Product Description
Mechanism Of Action
erythropoietin - Drug Profile
Product Description
Mechanism Of Action
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Protein to Agonize EPOR for Chemotherapy Induced Anemia and Renal Anemia - Drug Profile
Product Description
Mechanism Of Action
History of Events
itacnosertib - Drug Profile
Product Description
Mechanism Of Action
History of Events
JL-14001 - Drug Profile
Product Description
Mechanism Of Action
P-1116 - Drug Profile
Product Description
Mechanism Of Action
PHEP-01 - Drug Profile
Product Description
Mechanism Of Action
roxadustat - Drug Profile
Product Description
Mechanism Of Action
History of Events
TBI-304H - Drug Profile
Product Description
Mechanism Of Action
History of Events
Chemotherapy Induced Anemia - Dormant Projects
Chemotherapy Induced Anemia - Discontinued Products
Chemotherapy Induced Anemia - Product Development Milestones
Featured News & Press Releases
Aug 25, 2021: FibroGen announces positive topline results from phase 2 clinical trial of roxadustat for the treatment of chemotherapy induced anemia
Jul 23, 2020: Zydus receives approval from USFDA to initiate clinical trials of Desidustat in cancer patients receiving chemotherapy
Sep 26, 2019: FibroGen announces initiation of phase 2 clinical trial of Roxadustat for the treatment of anemia in cancer patients receiving chemotherapy
Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigational agent TP-0184 at AACR Annual Meeting 2019
Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chemotherapy Induced Anemia - Pipeline by Avesthagen Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by FibroGen Inc, 2022
Chemotherapy Induced Anemia - Pipeline by General Biologics Inc, 2022
Chemotherapy Induced Anemia - Pipeline by Imagine Pharma LLC, 2022
Chemotherapy Induced Anemia - Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corp, 2022
Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corp, 2022
Chemotherapy Induced Anemia - Pipeline by Resilience Biotechnologies Inc, 2022
Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022
Chemotherapy Induced Anemia - Pipeline by UBI Pharma Inc, 2022
Chemotherapy Induced Anemia - Pipeline by Vifor Pharma Ltd, 2022
Chemotherapy Induced Anemia - Pipeline by Zydus Lifesciences Ltd, 2022
Chemotherapy Induced Anemia - Dormant Projects, 2022
Chemotherapy Induced Anemia - Discontinued Products, 2022

List of Figures
Number of Products under Development for Chemotherapy Induced Anemia, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $2000.00
  • $4000.00
  • $6000.00
  • ADD TO BASKET
  • BUY NOW